Neurocrine Biosciences Reveals New INGREZZA Data at Psych Congress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: PRnewswire
- Clinical Trial Results: In the KINECT®4 clinical trial, 59% of patients achieved significant symptom remission over 48 weeks, demonstrating the efficacy of INGREZZA in treating tardive dyskinesia, thereby enhancing the company's competitive position in the mental health drug market.
- Post-Hoc Analysis Findings: Even among patients who did not meet the stringent remission criteria, 86% achieved a ≥30% reduction in total AIMS score, indicating INGREZZA's broad clinical impact in improving movement severity, which may attract more patients to its use.
- Hepatic Risk Factors Analysis: A retrospective analysis of over 176,000 newly diagnosed patients revealed that 90% had at least one hepatic risk factor, underscoring the importance of evaluating liver health in treatment decisions, which could influence the market acceptance of INGREZZA.
- Long-Term Treatment Effects: In the KINECT 4 study, patients experienced an average AIMS total score reduction of 10.2 to 11.0 points over 48 weeks, indicating INGREZZA's good tolerability and effectiveness in long-term treatment, further solidifying its position in treating tardive dyskinesia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBIX
Wall Street analysts forecast NBIX stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 159.000
Low
143.00
Averages
179.68
High
203.00
Current: 159.000
Low
143.00
Averages
179.68
High
203.00
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Long-Term Efficacy of VYKAT XR for Prader-Willi Syndrome
- Significant Treatment Effects: In a two-year study, participants resuming VYKAT XR showed durable improvements in hyperphagia and behavioral symptoms, reinforcing the drug's efficacy and safety as a long-term treatment for Prader-Willi syndrome (PWS).
- Clinical Trial Data: Results from Study C614 involving 77 participants indicated that those who resumed treatment experienced significant recovery in hyperphagia symptoms, while those on continuous therapy maintained notable improvements in hyperphagia and other PWS-related behaviors.
- Long-Term Follow-Up Study: Compared to 229 natural history controls, VYKAT XR demonstrated statistically significant improvements in hyperphagia scores at all evaluated time points over three years, highlighting the drug's sustained efficacy.
- Behavioral Improvement Analysis: Analysis of PWSP data from 105 VYKAT XR-treated participants revealed significant improvements across all six behavioral domains, further validating its potential application in PWS patients.
See More
Neurocrine Biosciences Reveals Clinical Findings on CAH Treatment
- Clinical Findings: Neurocrine Biosciences announced results from a retrospective case series involving 15 patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, demonstrating that treatment with CRENESSITY® (crinecerfont) led to significant reductions in androgen precursors and improved blood pressure, indicating the drug's potential in managing this rare CAH subtype.
- Hormonal Control Improvement: The study revealed that all patients with elevated baseline androgen levels experienced a decrease in steroid precursor levels to normal ranges after initiating CRENESSITY, with adult patients also showing improved blood pressure, underscoring the drug's efficacy in enhancing hormonal control.
- Clinical Significance: This case series provides critical clinical insights for managing patients with 11β-hydroxylase deficiency, aiding clinicians in treatment decisions amidst limited data, thus addressing a complex subgroup within classic CAH.
- Future Research Directions: Neurocrine emphasized its commitment to further exploring the application of CRENESSITY in classic CAH subtypes, reinforcing its dedication to advancing treatment options for patients with rare endocrine disorders.
See More
CRENESSITY Shows Significant Clinical Effects in Patients with 11β-Hydroxylase Deficiency
- Significant Efficacy: In patients with 11β-hydroxylase deficiency, CRENESSITY treatment resulted in over 90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone, demonstrating the drug's strong potential in hormone level control.
- Improved Medication Adherence: Among the 15 patients treated with CRENESSITY, 14 were able to reduce their total glucocorticoid dose, indicating the drug's effectiveness in reducing hormone dependency.
- Blood Pressure Improvement: Among patients receiving antihypertensive treatment, two were able to reduce or discontinue these medications, suggesting CRENESSITY's potential benefits in managing hypertension.
- Clinical Research Breakthrough: This retrospective case series provides initial clinical insights for patients with 11β-hydroxylase deficiency, highlighting the importance of CRENESSITY in treating classic congenital adrenal hyperplasia and promoting further research into this rare subtype.
See More
Long-Term Efficacy of VYKAT XR in Treating Prader-Willi Syndrome
- Significant Treatment Effects: Participants who resumed VYKAT XR after a 16-week randomized withdrawal period demonstrated marked improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits sustained over two years, indicating the drug's long-term efficacy in Prader-Willi syndrome (PWS) patients.
- Clinical Trial Data Support: Three-year data for VYKAT XR showed statistically significant improvements in hyperphagia scores compared to controls from the natural history study, with treatment differences of 6.2, 6.5, and 6.2 points at Year 1, Year 2, and Year 3, respectively, highlighting the drug's sustained effectiveness.
- Comprehensive Behavioral Improvements: Participants who resumed VYKAT XR exhibited significant improvements across all six behavioral domains of PWS over two years, particularly in anxiety, compulsivity, and aggression, further validating the multidimensional efficacy of the drug.
- Ongoing Safety Monitoring: Throughout the clinical trials, long-term use of VYKAT XR did not result in severe adverse reactions, and participants' body mass index (BMI) remained relatively stable, demonstrating the drug's ability to effectively manage overall health while treating hyperphagia.
See More
Neurocrine Reports Positive Two-Year Data for Crenessity in Pediatric CAH Study
- Clinical Trial Results: Neurocrine Biosciences reported positive two-year data from its CAHtalyst Pediatric study of Crenessity, indicating slowed bone age progression and improved predicted adult height in treated children and adolescents, demonstrating the drug's efficacy in managing classic congenital adrenal hyperplasia (CAH).
- Bone Age and Height Improvement: Among 41 growing patients, 24 with advanced bone age at baseline showed stable or improved bone age scores after 24 months, with a mean decrease of 1.12 standard deviations, while nine patients had reductions greater than two standard deviations, alongside a mean increase of 4.7 cm in predicted adult height, highlighting Crenessity's significant impact.
- Hormonal Control and Drug Use: The findings suggest that sustained hormonal control and reduced glucocorticoid use enabled by Crenessity may support improved growth outcomes in childhood and adolescence, emphasizing the drug's potential advantages in treatment.
- Positive Market Reaction: Following the announcement, NBIX shares rose over 1% in pre-market trading, closing at $159.76, reflecting market optimism regarding the positive clinical data and potentially driving future growth prospects for the company.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Long-Term Efficacy of VYKAT XR for Prader-Willi Syndrome
- Significant Treatment Effects: In a two-year study, participants resuming VYKAT XR showed durable improvements in hyperphagia and behavioral symptoms, reinforcing the drug's efficacy and safety as a long-term treatment for Prader-Willi syndrome (PWS).
- Clinical Trial Data: Results from Study C614 involving 77 participants indicated that those who resumed treatment experienced significant recovery in hyperphagia symptoms, while those on continuous therapy maintained notable improvements in hyperphagia and other PWS-related behaviors.
- Long-Term Follow-Up Study: Compared to 229 natural history controls, VYKAT XR demonstrated statistically significant improvements in hyperphagia scores at all evaluated time points over three years, highlighting the drug's sustained efficacy.
- Behavioral Improvement Analysis: Analysis of PWSP data from 105 VYKAT XR-treated participants revealed significant improvements across all six behavioral domains, further validating its potential application in PWS patients.
See More
Neurocrine Biosciences Reveals Clinical Findings on CAH Treatment
- Clinical Findings: Neurocrine Biosciences announced results from a retrospective case series involving 15 patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, demonstrating that treatment with CRENESSITY® (crinecerfont) led to significant reductions in androgen precursors and improved blood pressure, indicating the drug's potential in managing this rare CAH subtype.
- Hormonal Control Improvement: The study revealed that all patients with elevated baseline androgen levels experienced a decrease in steroid precursor levels to normal ranges after initiating CRENESSITY, with adult patients also showing improved blood pressure, underscoring the drug's efficacy in enhancing hormonal control.
- Clinical Significance: This case series provides critical clinical insights for managing patients with 11β-hydroxylase deficiency, aiding clinicians in treatment decisions amidst limited data, thus addressing a complex subgroup within classic CAH.
- Future Research Directions: Neurocrine emphasized its commitment to further exploring the application of CRENESSITY in classic CAH subtypes, reinforcing its dedication to advancing treatment options for patients with rare endocrine disorders.
See More
CRENESSITY Shows Significant Clinical Effects in Patients with 11β-Hydroxylase Deficiency
- Significant Efficacy: In patients with 11β-hydroxylase deficiency, CRENESSITY treatment resulted in over 90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone, demonstrating the drug's strong potential in hormone level control.
- Improved Medication Adherence: Among the 15 patients treated with CRENESSITY, 14 were able to reduce their total glucocorticoid dose, indicating the drug's effectiveness in reducing hormone dependency.
- Blood Pressure Improvement: Among patients receiving antihypertensive treatment, two were able to reduce or discontinue these medications, suggesting CRENESSITY's potential benefits in managing hypertension.
- Clinical Research Breakthrough: This retrospective case series provides initial clinical insights for patients with 11β-hydroxylase deficiency, highlighting the importance of CRENESSITY in treating classic congenital adrenal hyperplasia and promoting further research into this rare subtype.
See More
Long-Term Efficacy of VYKAT XR in Treating Prader-Willi Syndrome
- Significant Treatment Effects: Participants who resumed VYKAT XR after a 16-week randomized withdrawal period demonstrated marked improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits sustained over two years, indicating the drug's long-term efficacy in Prader-Willi syndrome (PWS) patients.
- Clinical Trial Data Support: Three-year data for VYKAT XR showed statistically significant improvements in hyperphagia scores compared to controls from the natural history study, with treatment differences of 6.2, 6.5, and 6.2 points at Year 1, Year 2, and Year 3, respectively, highlighting the drug's sustained effectiveness.
- Comprehensive Behavioral Improvements: Participants who resumed VYKAT XR exhibited significant improvements across all six behavioral domains of PWS over two years, particularly in anxiety, compulsivity, and aggression, further validating the multidimensional efficacy of the drug.
- Ongoing Safety Monitoring: Throughout the clinical trials, long-term use of VYKAT XR did not result in severe adverse reactions, and participants' body mass index (BMI) remained relatively stable, demonstrating the drug's ability to effectively manage overall health while treating hyperphagia.
See More
Neurocrine Reports Positive Two-Year Data for Crenessity in Pediatric CAH Study
- Clinical Trial Results: Neurocrine Biosciences reported positive two-year data from its CAHtalyst Pediatric study of Crenessity, indicating slowed bone age progression and improved predicted adult height in treated children and adolescents, demonstrating the drug's efficacy in managing classic congenital adrenal hyperplasia (CAH).
- Bone Age and Height Improvement: Among 41 growing patients, 24 with advanced bone age at baseline showed stable or improved bone age scores after 24 months, with a mean decrease of 1.12 standard deviations, while nine patients had reductions greater than two standard deviations, alongside a mean increase of 4.7 cm in predicted adult height, highlighting Crenessity's significant impact.
- Hormonal Control and Drug Use: The findings suggest that sustained hormonal control and reduced glucocorticoid use enabled by Crenessity may support improved growth outcomes in childhood and adolescence, emphasizing the drug's potential advantages in treatment.
- Positive Market Reaction: Following the announcement, NBIX shares rose over 1% in pre-market trading, closing at $159.76, reflecting market optimism regarding the positive clinical data and potentially driving future growth prospects for the company.
See More
